Never events and related quality measures following total hip and total knee replacement

Orthopedics

Volumn 33, Issue 11, 2010, Pages

  Kwong, Louis M ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CHRONIC VEIN INSUFFICIENCY; DEEP VEIN THROMBOSIS; DERMATITIS; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEMATOMA; HIGH RISK PATIENT; HUMAN; LEG PAIN; LEG SWELLING; LUNG EMBOLISM; MEDICAID; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEDICARE; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATIENT CARE; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; QUALITY CONTROL; QUALITY OF LIFE; REOPERATION; REVIEW; STASIS DERMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOGENESIS; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; ULCER; UNITED STATES; VENOUS THROMBOEMBOLISM; WOUND INFECTION; HEALTH CARE QUALITY; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; MORTALITY; POSTOPERATIVE COMPLICATION;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HUMANS; POSTOPERATIVE COMPLICATIONS; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 78651363687     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20100924-22     Document Type: Review

References (39)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158(6):585-593.
2. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. US Department of Health and Human Services 2008. http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on- dvt-2008.pdf. Accessed June 29, 2010.
3. Heit JA, Cohen AT, Anderson FA, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005; 106:Abstract 910.
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133 (6 suppl):381S-453S. (Pubitemid 351894916)
5. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008; 90(12):2764-2780.
6. Sharrock NE, Ranawat CS, Urquhart B, Peterson M. Factors influencing deep vein thrombosis following total hip arthroplasty under epidural anesthesia. Anesth Analg. 1993; 76(4):765-771. (Pubitemid 23107594)
7. Snow V, Qaseem A, Barry P, et al; and American College of Physicians; American Academy of Family Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians [published online ahead of print January 29, 2007]. Ann Intern Med. 2007; 146(3):204-210.
8. Lovenox (enoxaparin sodium injection) prescribing information. Sanofi-Aventis 2009. http://products.sanofi-aventis.us/lovenox/lovenox.pdf. Accessed June 29, 2010.
9. Caprini JA, Tapson VF, Hyers TM, et al; and NABOR Steering Committee. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005; 42(4):726-733.
10. Tapson VF, Hyers TM, Waldo AL, et al; and NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005; 165(13):1458-1464.
11. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr; Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008; 24(1):87-97.
12. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004; 164(20):2260-2265. (Pubitemid 39456437)
13. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999; 159(5):445-453.
14. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006; 21(1):23-29. (Pubitemid 43231124)
15. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160(6):761-768. (Pubitemid 30165236)
16. Caprini JA, Hyers TM. Compliance with antithrombotic guidelines. Manag Care. 2006; 15(9):49-50, 53-60, 66.
17. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005; 87(9):2097-2112. (Pubitemid 41279143)
18. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991; 303(6815):1431-1435.
19. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632):31-39.
20. Avorn J, Winkelmayer WC. Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation. 2004; 110(24 suppl 1):IV25-IV32. (Pubitemid 40018733)
21. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. US Agency for Healthcare Research and Quality. Agency for Healthcare Research and Quality 2001. http://www.ahrq.gov/clinic/ptsafety/pdf/ptsafety.pdf. Accessed June 29, 2010.
22. National Patient Safety Goals: Hospital Program. The Joint Commission 2009. http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/ 08-hap-npsgs.htm. Accessed June 29, 2010.
23. Preventing errors related to commonly used anticoagulants. The Joint Commission 2008. http://www.jointcommission.org/SentinelEvents/ SentinelEventAlert/sea-41.htm. Accessed June 29, 2010.
24. Medicare and Medicaid move aggressively to encourage greater patient safety in hospitals and reduce never events. Centers for Medicare & Medicaid Services Website. http://www.cms.hhs.gov/apps/media/press/release.asp?Counter= 3219&intNumPerPage=10&checkDate=&checkKey=&srchType= 1&numDays=3500&srchOpt=0&srchData=&keywordType= All&chkNewsType=1%2C+2%2C+3%2C+4%2C+&intPage=&showAll=&pYear= &year=&desc=false&cboOrder=date. Accessed June 29, 2010.
25. What is SCIP? Surgical Care Improvement Project (SCIP) 2008. http://premierinc.com/safety/topics/scip/index.jsp. Accessed June 29, 2010.
26. Physician Quality Reporting Initiative (PQRI). Centers for Medicare & Medicaid Services Website. http://www.cms.hhs.gov/pqri. Accessed June 29, 2010.
27. Medicare announces site for pilot program to improve quality as patients move across care settings [press release]. Centers for Medicare & Medicaid Services Website. http://www.cms.hhs.gov/apps/media/press/release.asp?Counter= 3439&intNumPerPage=10&checkDate=&checkKey=2&srchType= 2&numDays=0&srchOpt=0&srchData=move+across+care+settings& keywordType=All&chkNewsType=1%2C+2%2C+3%2C+4%2C+5&intPage=&showAll= 1&pYear=1&year=2009&desc=& cboOrder=date. Accessed June 29, 2010.
28. CMS announces demonstration to encourage greater collaboration and improve quality using bundled hospital payments [press release]. CMS Office of Public Affairs. http://www.cms.gov/apps/media/press/release.asp?Counter= 3109&intNumPerPage=10& checkDate=&checkKey=2&srchType= 2&numDays=0&srchOpt=0&srchData=cms+announces+demonstration& keywordType=All& chkNewsType=1%2C+2%2C+3%2C+4. Accessed June 29, 2010.
29. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009; 91(7):1756-1757.
30. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002; 137(8):648-655.
31. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet. 1993; 341(8840):259-265.
32. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 suppl):257S-298S.
33. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361(6):594-604.
34. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375(9717):807-815.
35. Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949-956.
36. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery [published online ahead of print April 14, 2008]. J Arthroplasty. 2009; 24(1):1-9.
37. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-2775.
38. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-2786.
39. Turpie AGG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial [published online ahead of print May 4, 2009]. Lancet. 2009; 373(9676):1673-1680.